← Back to patent-cliff list
Tolvaptan Sodium Phosphate
Tier C — Watch / tradeTolvaptan Sodium Phosphate
Otsuka Pharmaceutical Co., Ltd.
Originator
2022
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：V2R
Brand：Samtasu
Indications (approved)：Heart failure
Regional status
US
-
EU
-
China
Approved
2025-09-30
Japan
Approved
2022-03-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tolvaptan Sodium Phosphate?
Approved indications include: Heart failure.
When does the Tolvaptan Sodium Phosphate patent expire?
No public expiry year is available for Tolvaptan Sodium Phosphate yet; this page updates once verified.
How do I get a quote for Tolvaptan Sodium Phosphate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01